Recon: Pfizer raises outlook by $1.5B over renewed Paxlovid sales; Lilly touts new dosing regimen for Alzheimer’s drug as potentially safer
ReconJason Scott
Biologics/ biosimilars/ vaccinesEuropeGlobalMedical DevicesNorth AmericaPharmaceuticalsRegulatory Intelligence/PolicyUnited States